Akari Therapeutics Plc (AKTX) financial statements (2023 and earlier)

Company profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments68,9206,216
Cash and cash equivalents68,9206,216
Restricted cash and investments 142
Receivables10 
Other undisclosed current assets72873
Total current assets:69,6586,431
Noncurrent Assets
Property, plant and equipment4149
Intangible assets, net (including goodwill)52 
Intangible assets, net (excluding goodwill)52 
Restricted cash and investments142 
Total noncurrent assets:23549
TOTAL ASSETS:69,8946,480
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,7291,715
Accounts payable4,3211,359
Accrued liabilities408352
Employee-related liabilities 4
Due to related parties 118
Other undisclosed current liabilities16,396(474)
Total current liabilities:21,1251,359
Noncurrent Liabilities
Liabilities, other than long-term debt 33
Other liabilities 33
Other undisclosed noncurrent liabilities49235
Total noncurrent liabilities:49268
Total liabilities:21,1741,627
Stockholders' equity
Stockholders' equity attributable to parent48,7204,853
Common stock18,341927
Additional paid in capital87,01934,116
Accumulated other comprehensive income156 
Accumulated deficit(56,797)(30,190)
Total stockholders' equity:48,7204,853
TOTAL LIABILITIES AND EQUITY:69,8946,480

Income statement (P&L) ($ in thousands)

12/31/2015
12/31/2014
Revenues
(Financial Services Revenue)
 549
Cost of revenue
(Financial Services Costs)
(22,973) 
Gross profit:(22,973)549
Operating expenses(30,585)(10,177)
Other undisclosed operating income (loss)22,973(549)
Operating loss:(30,585)(10,177)
Nonoperating income (expense)(14,733)529
Other nonoperating income 529
Interest and debt expense(3,054) 
Loss from continuing operations before equity method investments, income taxes:(48,371)(9,648)
Other undisclosed income from continuing operations before income taxes3,054 
Net loss available to common stockholders, diluted:(45,318)(9,648)

Comprehensive Income ($ in thousands)

12/31/2015
12/31/2014
Net loss:(45,318)(9,648)
Comprehensive loss:(45,318)(9,648)
Other undisclosed comprehensive income, net of tax, attributable to parent110 
Comprehensive loss, net of tax, attributable to parent:(45,207)(9,648)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: